Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 06, 2024

BUY
$1.22 - $5.24 $22,360 - $96,038
18,328 Added 157.9%
29,935 $37,000
Q2 2023

Aug 09, 2023

BUY
$4.09 - $8.29 $47,472 - $96,222
11,607 New
11,607 $50,000

Others Institutions Holding BIVI

About BIOVIE INC.


  • Ticker BIVI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,165,300
  • Market Cap $68.5M
  • Description
  • BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial ...
More about BIVI
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.